ZA96796B - Transdermal formulation. - Google Patents

Transdermal formulation.

Info

Publication number
ZA96796B
ZA96796B ZA9600796A ZA96796A ZA96796B ZA 96796 B ZA96796 B ZA 96796B ZA 9600796 A ZA9600796 A ZA 9600796A ZA 96796 A ZA96796 A ZA 96796A ZA 96796 B ZA96796 B ZA 96796B
Authority
ZA
South Africa
Prior art keywords
transdermal formulation
transdermal
formulation
Prior art date
Application number
ZA9600796A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Lisa Ann Shipley
Kirti Himatlal Valia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA96796B publication Critical patent/ZA96796B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA9600796A 1995-02-17 1996-02-01 Transdermal formulation. ZA96796B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/390,447 US5605701A (en) 1995-02-17 1995-02-17 Transdermal formulation

Publications (1)

Publication Number Publication Date
ZA96796B true ZA96796B (en) 1997-08-01

Family

ID=23542490

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9600796A ZA96796B (en) 1995-02-17 1996-02-01 Transdermal formulation.

Country Status (7)

Country Link
US (1) US5605701A (de)
EP (1) EP0727209A2 (de)
AU (1) AU4914396A (de)
IL (1) IL116999A0 (de)
PE (1) PE17997A1 (de)
WO (1) WO1996025042A1 (de)
ZA (1) ZA96796B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239732A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use

Also Published As

Publication number Publication date
IL116999A0 (en) 1996-06-18
EP0727209A2 (de) 1996-08-21
WO1996025042A1 (en) 1996-08-22
PE17997A1 (es) 1997-06-04
US5605701A (en) 1997-02-25
AU4914396A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
ZA967084B (en) Cement formulation.
ZA966148B (en) Novel formulation.
ZA962338B (en) Oral 2-methyl-thieno-benzodiazepine formulation.
ZA967315B (en) Biphenylamides.
ZA965190B (en) Pharmaceutical composition.
ZA966075B (en) Protein formulation.
HU9603495D0 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, as pharmaceutical agents
ZA961444B (en) Pyrazolylbenzoyl derivatives.
MX213417B (es) Fenilpiridazinonas.
CY2359B1 (en) Pharmaceutical formulation.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA96530B (en) Transdermal formulation
ZA961449B (en) Isoxazolylbenzoyl derivatives.
IL116997A0 (en) Transdermal formulation
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA968081B (en) Pharmaceutical composition.
ZA96796B (en) Transdermal formulation.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA966399B (en) Endothelin-receptor-antagonists.
ZA965494B (en) Therapeutic agents.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA966750B (en) Halogenobenzimidazoles.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA967314B (en) Carbamoylcarboxamides.